Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...